'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in debut

'A fourth revolution in cancer therapies': ARCH-backed Boundless Bio flashes big check, makes bigger promises in debut

Source: 
Endpoints
snippet: 

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

That insight and the ensuing five years of research will now get $46 million cash and company infrastructure to ramp into targeted therapies as Boundless Bio emerges from stealth mode with backing from ARCH Venture Partners and City Hill. Questions abound, from what precisely a drug would look like to what even gives rise to these wild DNA, but CEO Zachary Hornby isn’t biting his tongue on the potential.